USV Expands Diabetes Portfolio with Cost-Effective Liralin-EP in India - Video

Published On 2025-03-22T13:00:32+05:30 | Updated On 24 March 2025 4:37 PM IST

Overview

USV Pvt. Ltd., launches the Liralin EP a combination of Linagliptin & Empagliflozin at just Rs 12.90 per tablet for strengthening it's affordable diabetes care range. Liralin EP contains the world's 1st approved DPP4i + SGLT2i combination for the management.

It is available in two strengths to cater to varied patient needs- Liralin-EP 10 contains Empagliflozin 10 mg and Linagliptin 5 mg, while Liralin-EP 25 contains Empagliflozin 25 mg and Linagliptin 5 mg.

Given the loss of patency of Empagliflozin in India, USV has priced the drug at very affordable levels for the convenience of patients. Liralin-EP 10 at ₹12.90 per tablet and Liralin-EP 25 at ₹13.90 per tablet, making quality diabetes management accessible to a wider patient population across India.

Liralin-EP combines Linagliptin, a DPP-4 inhibitor, with Empagliflozin, an SGLT2 inhibitor, offering complementary mechanisms to effectively lower blood glucose levels while providing added cardiovascular and renal benefits.

Speakers

Dr. Nandita Mohan

Dr. Nandita Mohan is a practicing pediatric dentist with more than 5 years of clinical work experience. Along with this, she is equally interested in keeping herself up to date about the latest developments in the field of medicine and dentistry which is the driving force for her to be in association with Medical Dialogues. She also has her name attached with many publications; both national and international. She has pursued her BDS from Rajiv Gandhi University of Health Sciences, Bangalore and later went to enter her dream specialty (MDS) in the Department of Pedodontics and Preventive Dentistry from Pt. B.D. Sharma University of Health Sciences. Through all the years of experience, her core interest in learning something new has never stopped. She can be contacted at editorial@medicaldialogues.in. Contact no. 011-43720751